Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Posted on: Tuesday, 9 December 2008, 07:00 CST
The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic data from this study show that systemic plasma levels of the active agents of OMS201 in patients were minimal and in most cases below the level of quantification. There were no serious adverse events.
"We continue to be encouraged by the progress being made in our OMS201 development program, and the completion of this study represents another successful milestone as we advance our PharmacoSurgery(TM) platform," stated
The Phase 1 study was a randomized, double-blind, vehicle-controlled and parallel-assigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgeryTM platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to standard irrigation solutions in urological surgery, OMS201 is delivered during the operation directly to the surgical site to inhibit surgically induced inflammation, pain and smooth muscle spasm.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.
SOURCE Omeros Corporation
Source: PR Newswire
Related Articles
- Studies Show LAM Patients Participate in Clinical Trials to Help Others
- Bariatric Surgery Patients Have 65 Percent Lower Chance of Complications at Top-Performing Hospitals: HealthGrades Study
- St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
- Second Sight Completes U.S. Phase I Enrollment and Commences European Clinical Trial for the Argus II Retinal Implant
- CombinatoRx Announces Initiation of Phase 2a Proof-of-Concept Clinical Study With CRx-401 for Type 2 Diabetes
- HealthGrades Study: Bariatric Surgery Patients Have Fewer Complications at High-Volume Hospitals
- Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
- Concern Over Heart Devices Hindering National Study: Only One Patient From Heart Clinic Willing to Enroll in Experiment
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds